2024-03-28T16:11:18Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_8512C8B4A7E1
2024-03-23T02:37:54Z
serval:BIB_8512C8B4A7E1
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
10.1016/j.jtho.2020.10.129
000632634700017
33188912
Peters
S.
author
Felip
E.
author
Dafni
U.
author
Tufman
A.
author
Guckenberger
M.
author
Álvarez
R.
author
Nadal
E.
author
Becker
A.
author
Vees
H.
author
Pless
M.
author
Martinez-Marti
A.
author
Lambrecht
M.
author
Andratschke
N.
author
Tsourti
Z.
author
Piguet
A.C.
author
Roschitzki-Voser
H.
author
Gasca-Ruchti
A.
author
Vansteenkiste
J.
author
Stahel
R.A.
author
De Ruysscher
D.
author
article
2021-02
Journal of thoracic oncology
1556-1380
1556-0864
journal
16
2
278-288
Chemoradiotherapy
Immune checkpoint inhibition
NSCLC
Nivolumab
eng
60_published
true
peer-reviewed
Publication types: Journal Article
Publication Status: ppublish